M-type Phospholipase A2 Receptor Autoantibodies and Renal Function in Patients with Primary Membranous Nephropathy

被引:89
作者
Hoxha, Elion [1 ]
Harendza, Sigrid [1 ]
Pinnschmidt, Hans [2 ]
Panzer, Ulf [1 ]
Stahl, Rolf A. K. [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med 3, D-20246 Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, D-20246 Hamburg, Germany
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2014年 / 9卷 / 11期
关键词
CYCLOPHOSPHAMIDE; ANTIBODIES; RITUXIMAB; PROGNOSIS; ELISA;
D O I
10.2215/CJN.03850414
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives Loss of renal function in patients with primary membranous nephropathy cannot be reliably predicted by laboratory or clinical markers at the time of diagnosis. M-type phospholipase A(2) receptor autoantibodies have been shown to be associated with changes in proteinuria. Their eventual effect on renal function, however, is unclear. Design, setting, participants, & measurements In this prospective, open, multicenter study, the potential role of M-type phospholipase A(2) receptor autoantibodies levels on the increase of serum creatinine in 118 consecutive patients with membranous nephropathy and positivity for serum M-type phospholipase A(2) receptor autoantibodies was analyzed. Patients were included in the study between April of 2010 and December of 2012 and observed until December of 2013. The clinical end point was defined as an increase of serum creatinine by >= 25% and serum creatinirte reaching mg/dl. Results Patients were divided into tertiles according to their M-type phospholipase A(2) receptor autoantibody levels at the time of inclusion in the study: tertile 1 levels=20-86 units/ml (low), tertile 2 levels=87-201 units/ml (medium), and tertile 3 levels >= 202 units/ml (high). The median follow-up time of all patients in the study was 27 months (interquartile range=18-33 months). The clinical end point was reached in 69% of patients with high M-type phospholipase A(2) receptor autoantibodies levels (tertile 3) but only 25% of patients with low M-type phospholipase A(2) receptor autoantibodies levels. The average time to reach the study end point was 17.7 months in patients with high M-type phospholipase A(2) receptor autoantibodies levels and 30.9 months in patients with low M-type phospholipase A(2) receptor autoantibodies levels. A multivariate Cox regression analysis showed that high M-type phospholipase A(2) receptor autoantibodies levels in addition to men and older age are an independent predictor for progressive loss of renal function. Conclusions High M-type phospholipase A(2) receptor autoantibodies levels were associated with more rapid loss of renal function in this cohort of patients with primary membranous nephropathy and therefore, could be helpful for treatment decisions.
引用
收藏
页码:1883 / 1890
页数:8
相关论文
共 21 条
  • [11] Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy
    Hofstra, Julia M.
    Beck, Laurence H., Jr.
    Beck, David M.
    Wetzels, Jack F.
    Salant, David J.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (06): : 1286 - 1291
  • [12] Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial
    Howman, Andrew
    Chapman, Tracey L.
    Langdon, Maria M.
    Ferguson, Caroline
    Adu, Dwomoa
    Feehally, John
    Gaskin, Gillian J.
    Jayne, David R. W.
    O'Donoghue, Donal
    Boulton-Jones, Michael
    Mathieson, Peter W.
    [J]. LANCET, 2013, 381 (9868) : 744 - 751
  • [13] Phospholipase A2 Receptor Autoantibodies and Clinical Outcome in Patients with Primary Membranous Nephropathy
    Hoxha, Elion
    Thiele, Ina
    Zahner, Gunther
    Panzer, Ulf
    Harendza, Sigrid
    Stahl, Rolf A. K.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 25 (06): : 1357 - 1366
  • [14] An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis
    Hoxha, Elion
    Harendza, Sigrid
    Zahner, Gunter
    Panzer, Ulf
    Steinmetz, Oliver
    Fechner, Kai
    Helmchen, Udo
    Stahl, Rolf A. K.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (08) : 2526 - 2532
  • [15] A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy
    Jha, Vivekanand
    Ganguli, Anirban
    Saha, Tarun K.
    Kohli, Harbir S.
    Sud, Kamal
    Gupta, Krishan L.
    Joshi, Kusum
    Sakhuja, Vinay
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (06): : 1899 - 1904
  • [16] Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy
    Kanigicherla, Durga
    Gummadova, Jennet
    McKenzie, Edward A.
    Roberts, Stephen A.
    Harris, Shelley
    Nikam, Milind
    Poulton, Kay
    McWilliam, Lorna
    Short, Colin D.
    Venning, Michael
    Brenchley, Paul E.
    [J]. KIDNEY INTERNATIONAL, 2013, 83 (05) : 940 - 948
  • [17] Calcineurin Inhibitor Nephrotoxicity
    Naesens, Maarten
    Kuypers, Dirk R. J.
    Sarwal, Minnie
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (02): : 481 - 508
  • [18] Ponticelli C, 1998, J AM SOC NEPHROL, V9, P444
  • [19] Rituximab in Idiopathic Membranous Nephropathy
    Ruggenenti, Piero
    Cravedi, Paolo
    Chianca, Antonietta
    Perna, Annalisa
    Ruggiero, Barbara
    Gaspari, Flavio
    Rambaldi, Alessandro
    Marasa, Maddalena
    Remuzzi, Giuseppe
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (08): : 1416 - 1425
  • [20] PROGNOSIS OF UNTREATED PATIENTS WITH IDIOPATHIC MEMBRANOUS NEPHROPATHY
    SCHIEPPATI, A
    MOSCONI, L
    PERNA, A
    MECCA, G
    BERTANI, T
    GARATTINI, S
    REMUZZI, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (02) : 85 - 89